- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.04. | Roche's ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC | ||
| 19.04. | Ipsen announces launch of new UK headquarters in London life sciences community | ||
| 19.04. | GSK's shingles vaccine shown to maintain high protection in long-term study | ||
| 19.04. | UK scientists discover two genes offering potential drug targets against skin cancer | ||
| 19.04. | Behavioural science - the route to healthcare salvation? | ||
| 18.04. | Takeda gains rights to Kumquat's immune-oncology programme in deal worth over $1.2bn | ||
| 18.04. | Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS | ||
| 18.04. | Novartis presents positive long-term data for relapsing MS treatment Kesimpta | ||
| 18.04. | UK scientists reveal promising new treatment strategy for acute myeloid leukaemia | ||
| 18.04. | Women's health - managing the menopause | ||
| 17.04. | Roche receives FDA breakthrough device designation for Alzheimer's disease blood test | ||
| 17.04. | Sanofi presents promising results for investigational frexalimab in relapsing forms of MS | ||
| 17.04. | Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy | ||
| 17.04. | AstraZeneca study reveals increasing number of people impacted by chronic kidney disease | ||
| 17.04. | Havas Life Medicom and Sciterion appoint Dick Dunford as group creative director | ||
| 16.04. | Novartis' blood cancer therapy Kymriah recommended by NICE for routine NHS use | ||
| 16.04. | AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer | ||
| 16.04. | European Parliament approves pharma reform compromise for equal access to new medicines | ||
| 16.04. | FDA establishes new CDER centre focused on promoting clinical trial innovation | ||
| 15.04. | AstraZeneca's Fasenra receives FDA approval for paediatric patients with severe asthma | ||
| 15.04. | Takeda's Takhzyro granted MHRA approval for younger hereditary angioedema patients | ||
| 15.04. | Roche's Columvi combination shows promise as second-line DLBCL therapy | ||
| 15.04. | ICR scientists reveal new ways to convert inhibitor-style targeted cancer drugs into degraders | ||
| 12.04. | Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition | ||
| 12.04. | AbbVie's oral therapy Aquipta recommended by NICE for migraine prevention in adults |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
